Related Experiment Videos
CLX-0901 (Calyx Therapeutics)
11st Chim Farmaceutico/Tossicologico, University of Milan, Italy. daniela.barlocco@unimi.it
Current Opinion in Investigational Drugs (London, England : 2000)
|September 25, 2001
Abstract:
Calyx Therapeutics is developing the insulin sensitizer, CLX-0901, as an antidiabetic agent. CLX-0901 is the synthetic analog of CLX-0900 which was originally isolated from a plant source. Phase I and toxicological studies indicate that the compound is safe and well tolerated [363764]. As of March 2001, phase II studies had commenced [402737]. Other antidiabetics being investigated by Calyx include CLX-0301, CLX-0921, CLX-0940, CLX-0100 and CLX-0101 [376032].